205 related articles for article (PubMed ID: 16596397)
21. Identification of novel Urotensin-II receptor antagonists with potent inhibition of U-II induced pressor response in mice.
Tandon R; Soni A; Singh RK; Sodhi R; Seth MK; Sinha S; Sahdev S; Dhage G; Das B; Dastidar SG; Shriumalla RK; Yonesu K; Marumoto S; Nagayama T
Eur J Pharmacol; 2020 Nov; 886():173391. PubMed ID: 32745605
[TBL] [Abstract][Full Text] [Related]
22. Ligand-supported purification of the urotensin-II receptor.
Du AT; Onan D; Dinh DT; Lew MJ; Ziogas J; Aguilar MI; Pattenden LK; Thomas WG
Mol Pharmacol; 2010 Oct; 78(4):639-47. PubMed ID: 20647393
[TBL] [Abstract][Full Text] [Related]
23. Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines.
Douglas SA; Naselsky D; Ao Z; Disa J; Herold CL; Lynch F; Aiyar NV
Br J Pharmacol; 2004 Jul; 142(6):921-32. PubMed ID: 15210573
[TBL] [Abstract][Full Text] [Related]
24. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
[TBL] [Abstract][Full Text] [Related]
25. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.
Olianas MC; Concas D; Onali P
Br J Pharmacol; 2006 Feb; 147(4):360-70. PubMed ID: 16402046
[TBL] [Abstract][Full Text] [Related]
26. Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues.
Behm DJ; McAtee JJ; Dodson JW; Neeb MJ; Fries HE; Evans CA; Hernandez RR; Hoffman KD; Harrison SM; Lai JM; Wu C; Aiyar NV; Ohlstein EH; Douglas SA
Br J Pharmacol; 2008 Oct; 155(3):374-86. PubMed ID: 18587423
[TBL] [Abstract][Full Text] [Related]
27. Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands.
Zhu J; Luo LY; Li JG; Chen C; Liu-Chen LY
J Pharmacol Exp Ther; 1997 Aug; 282(2):676-84. PubMed ID: 9262330
[TBL] [Abstract][Full Text] [Related]
28. Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay.
Brkovic A; Hattenberger A; Kostenis E; Klabunde T; Flohr S; Kurz M; Bourgault S; Fournier A
J Pharmacol Exp Ther; 2003 Sep; 306(3):1200-9. PubMed ID: 12807997
[TBL] [Abstract][Full Text] [Related]
29. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.
Behm DJ; Harrison SM; Ao Z; Maniscalco K; Pickering SJ; Grau EV; Woods TN; Coatney RW; Doe CP; Willette RN; Johns DG; Douglas SA
Br J Pharmacol; 2003 May; 139(2):464-72. PubMed ID: 12770952
[TBL] [Abstract][Full Text] [Related]
30. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures.
Siehler S; Nunn C; Zupanc GK; Hoyer D
Auton Autacoid Pharmacol; 2005 Jan; 25(1):1-16. PubMed ID: 15659149
[TBL] [Abstract][Full Text] [Related]
31. A Novel and Highly Potent Urotensin II Receptor Antagonist Inhibits Urotensin II-Induced Pressure Response in Mice.
Nishi M; Yonesu K; Tagawa H; Kato M; Marumoto S; Nagayama T
J Cardiovasc Pharmacol; 2019 Jan; 73(1):15-21. PubMed ID: 30608334
[TBL] [Abstract][Full Text] [Related]
32. An investigation of whether agonist-selective receptor conformations occur with respect to M2 and M4 muscarinic acetylcholine receptor signalling via Gi/o and Gs proteins.
Mistry R; Dowling MR; Challiss RA
Br J Pharmacol; 2005 Feb; 144(4):566-75. PubMed ID: 15655507
[TBL] [Abstract][Full Text] [Related]
33. Cloning and pharmacological characterization of the cat urotensin-II receptor (UT).
Aiyar N; Johns DG; Ao Z; Disa J; Behm DJ; Foley JJ; Buckley PT; Sarau HM; van-der-Keyl HK; Elshourbagy NA; Douglas SA
Biochem Pharmacol; 2005 Apr; 69(7):1069-79. PubMed ID: 15763543
[TBL] [Abstract][Full Text] [Related]
34. Comparative analysis of functional assays for characterization of agonist ligands at G protein-coupled receptors.
Niedernberg A; Tunaru S; Blaukat A; Harris B; Kostenis E
J Biomol Screen; 2003 Oct; 8(5):500-10. PubMed ID: 14567777
[TBL] [Abstract][Full Text] [Related]
35. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents.
Camarda V; Rizzi A; Calò G; Gendron G; Perron SI; Kostenis E; Zamboni P; Mascoli F; Regoli D
Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):141-9. PubMed ID: 11819032
[TBL] [Abstract][Full Text] [Related]
36. A real-time, fluorescence-based assay for measuring μ-opioid receptor modulation of adenylyl cyclase activity in Chinese hamster ovary cells.
Knapman A; Abogadie F; McIntrye P; Connor M
J Biomol Screen; 2014 Feb; 19(2):223-31. PubMed ID: 23989451
[TBL] [Abstract][Full Text] [Related]
37. New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide.
Grieco P; Carotenuto A; Campiglia P; Gomez-Monterrey I; Auriemma L; Sala M; Marcozzi C; d'Emmanuele di Villa Bianca R; Brancaccio D; Rovero P; Santicioli P; Meini S; Maggi CA; Novellino E
J Med Chem; 2009 Jul; 52(13):3927-40. PubMed ID: 19432421
[TBL] [Abstract][Full Text] [Related]
38. Desensitisation of native and recombinant human urotensin-II receptors.
Batuwangala MS; Calo G; Guerrini R; Ng LL; McDonald J; Lambert DG
Naunyn Schmiedebergs Arch Pharmacol; 2009 Nov; 380(5):451-7. PubMed ID: 19680632
[TBL] [Abstract][Full Text] [Related]
39. Down-regulation of GABA(A) receptor via promiscuity with the vasoactive peptide urotensin II receptor. Potential involvement in astrocyte plasticity.
Desrues L; Lefebvre T; Lecointre C; Schouft MT; Leprince J; Compère V; Morin F; Proust F; Gandolfo P; Tonon MC; Castel H
PLoS One; 2012; 7(5):e36319. PubMed ID: 22563490
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological characterization of type 1alpha metabotropic glutamate receptor-stimulated [35S]-GTPgammaS binding.
Akam EC; Carruthers AM; Nahorski SR; Challiss RA
Br J Pharmacol; 1997 Jul; 121(6):1203-9. PubMed ID: 9249258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
